{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T04:01:28Z","timestamp":1790136088048,"version":"4.0.1"},"reference-count":15,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.eimc.2020.09.016","type":"journal-article","created":{"date-parts":[[2020,11,13]],"date-time":"2020-11-13T02:04:53Z","timestamp":1605233093000},"page":"131-133","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["In vitro activity of delafloxacin against highly levofloxacin-resistant invasive isolates of Streptococcus pneumoniae"],"prefix":"10.1016","volume":"40","author":[{"given":"Emilia","family":"Cercenado","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Loras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Cobos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Carlos","family":"Sanz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eimc.2020.09.016_bib0080","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/QCO.0000000000000526","article-title":"New antibiotics for community-acquired pneumonia","volume":"32","author":"Kollef","year":"2019","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.eimc.2020.09.016_bib0085","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1080\/17476348.2019.1562339","article-title":"The burden of community-acquired bacterial pneumonia in the era of antibiotic resistance","volume":"13","author":"Peyrani","year":"2019","journal-title":"Expert Rev Respir Med"},{"key":"10.1016\/j.eimc.2020.09.016_bib0090","doi-asserted-by":"crossref","first-page":"e60273","DOI":"10.1371\/journal.pone.0060273","article-title":"Estimating the burden of pneumococcal pneumonia among adults: a systematic review and meta-analysis of diagnostic techniques","volume":"8","author":"Said","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.eimc.2020.09.016_bib0095","first-page":"61","article-title":"In vitro activity of delafloxacin against contemporary bacterial pathogens from the United States and Europe, 2014","author":"Pfaller","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.eimc.2020.09.016_bib0100","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.ijantimicag.2016.08.012","article-title":"Pharmacodynamic and pharmacokinetic profiling of delafloxacin in a murine lung model against community-acquired respiratory tract pathogens","volume":"48","author":"Thabit","year":"2016","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.eimc.2020.09.016_bib0105","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.2217\/fmb.15.39","article-title":"Delafloxacin, a non-zwitterionic fluoroquinolone in phase III of clinical development: evaluation of its pharmacology, pharmacokinetics, pharmacodynamics and clinical efficacy","volume":"10","author":"Van Bambeke","year":"2015","journal-title":"Future Microbiol"},{"key":"10.1016\/j.eimc.2020.09.016_bib0110","doi-asserted-by":"crossref","first-page":"ofz514","DOI":"10.1093\/ofid\/ofz514","article-title":"A phase 3 study to compare delafloxacin with moxifloxacin for the treatment of adults with community-acquired bacterial pneumonia (DEFINE-CABP)","volume":"7","author":"Horcajada","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.eimc.2020.09.016_bib0115","unstructured":"The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 10.0, 2020. http:\/\/www.eucast.org."},{"key":"10.1016\/j.eimc.2020.09.016_bib0120","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.micinf.2012.01.012","article-title":"Streptococcus pneumoniae: the evolution of antimicrobial resistance to beta-lactams, fluoroquinolones and macrolides","volume":"14","author":"Cornick","year":"2012","journal-title":"Microbes Infect"},{"key":"10.1016\/j.eimc.2020.09.016_bib0125","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s40121-018-0198-x","article-title":"Delafloxacin: place in therapy and review of microbiologic, clinical and pharmacologic properties","volume":"7","author":"Jorgensen","year":"2018","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.eimc.2020.09.016_bib0130","doi-asserted-by":"crossref","first-page":"6381","DOI":"10.1128\/AAC.00941-16","article-title":"In vitro activity of delafloxacin tested against isolates of Streptococcus pneumoniae Haemophilus influenzae, and Moraxella catarrhalis","volume":"60","author":"Flamm","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.eimc.2020.09.016_bib0135","doi-asserted-by":"crossref","first-page":"e01949","DOI":"10.1128\/AAC.01949-19","article-title":"Efficacy of delafloxacin versus moxifloxacin against bacterial respiratory pathogens in adults with community-acquired bacterial pneumonia (CABP): microbiology results from the delafloxacin phase 3 CABP trial","volume":"64","author":"McCurdy","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.eimc.2020.09.016_bib0140","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1128\/AAC.01380-10","article-title":"Clonal spread of levofloxacin-resistant Streptococcus pneumoniae invasive isolates in Madrid Spain, 2007 to 2009","volume":"55","author":"Rodr\u00edguez-Avial","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.eimc.2020.09.016_bib0145","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.eimc.2019.05.006","article-title":"Increase of serotype 8, ST53 clone, as the prevalent strain of Streptococcus pneumoniae causing invasive disease in Madrid, Spain (2012\u20132015)","volume":"38","author":"Sanz","year":"2020","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"10.1016\/j.eimc.2020.09.016_bib0150","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1093\/jac\/dkg469","article-title":"Emergence of a fluoroquinolone-resistant strain of Streptococcus pneumoniae in England","volume":"52","author":"Johnson","year":"2003","journal-title":"J Antimicrob Chemother"}],"container-title":["Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0213005X20303104?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0213005X20303104?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T13:07:46Z","timestamp":1759324066000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0213005X20303104"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":15,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["S0213005X20303104"],"URL":"https:\/\/doi.org\/10.1016\/j.eimc.2020.09.016","relation":{},"ISSN":["0213-005X"],"issn-type":[{"value":"0213-005X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vitro activity of delafloxacin against highly levofloxacin-resistant invasive isolates of Streptococcus pneumoniae","name":"articletitle","label":"Article Title"},{"value":"Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eimc.2020.09.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. Published by Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}